公开(公告)号：US20130295116A1

公开(公告)日：2013-11-07

申请号：US13920585

申请日：2013-06-18

Applicant: Novo Nordisk A/S

Inventor： Stefan Zahn ,  Louise Hjerrild Zeuthen ,  Anker Jon Hansen ,  Kristian Kjaergaard ,  Soeren Lund

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.